{"product_id":"abcam-ab259033","title":"Abcam, ab259033, Human PATL1 (Pat1b) knockout HeLa cell lysate","description":"\u003cp\u003eSize: 1Kit\u003cbr\u003e\nPATL1 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR\/Cas9, 1 bp insertion in exon 6 and Insertion of the selection cassette in exon 6.\u003cbr\u003e\nKey facts\u003cbr\u003e\nCell type:HeLa,\u003cbr\u003e\nSpecies or organism:Human,\u003cbr\u003e\nTissue:Cervix,\u003cbr\u003e\nKnockout validation:Sanger Sequencing,\u003cbr\u003e\nMutation description:Knockout achieved by using CRISPR\/Cas9, 1 bp insertion in exon 6 and Insertion of the selection cassette in exon 6.,\u003cbr\u003e\nDisease:Adenocarcinoma\u003c\/p\u003e\n\n\u003cp\u003eProduct details:\u003cbr\u003e\nKnockout cell lysate achieved by CRISPR\/Cas9.\u003cbr\u003e\nREACH authorisation\u003cbr\u003e\nAbcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.\u003cbr\u003e\nIt is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.\u003cbr\u003e\nLysate preparation:\u003cbr\u003e\nOur lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).\u003cbr\u003e\nThis means that the protein of interest is denatured.\u003cbr\u003e\nIf you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.\u003cbr\u003e\nUser storage instructions:\u003cbr\u003e\nLyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.\u003cbr\u003e\nThis product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our\u003cbr\u003e\nlimited use license\u003cbr\u003e\npatent pages\u003c\/p\u003e\n\n\u003cp\u003eProperties and Storage Information:\u003cbr\u003e\nGene name-PATL1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C\u003c\/p\u003e\n\n\u003cp\u003eSupplementary Information:\u003cbr\u003e\nThis supplementary information is collated from multiple sources and compiled automatically.\u003cbr\u003e\nPat1b also known as Processing body component 4 (PATI-4) is a protein with a mass of approximately 73 kDa. It functions mechanically as an RNA-binding protein involved in mRNA decay. Pat1b enhances mRNA decay by promoting decapping and subsequently exonucleolytic degradation. It is expressed in various human tissues with prominent activity reported in the brain and testes. In molecular biology labs Pat1b is regularly studied due to its central role in mRNA turnover.\u003cbr\u003e\nBiological function summary\u003cbr\u003e\nThe degradation of mRNA represents a critical step where Pat1b plays an essential role. As a component of the Pat1-Lsm complex Pat1b interacts with several proteins to regulate the stability and translation of mRNA. Pat1b influences the mRNA decapping process which is vital for controlled mRNA degradation thereby controlling gene expression post-transcriptionally. This process ensures the removal of aberrant or unnecessary mRNAs from the cellular environment enabling the cell to adapt to new conditions or signals rapidly.\u003cbr\u003e\nPathways\u003cbr\u003e\nMRNA decay and processing pathways involve Pat1b as a central component. Within the mRNA surveillance pathway Pat1b cooperates with Dcp1-Dcp2 decapping enzymes to mediate mRNA decay. Pat1b is pivotal in the nonsense-mediated mRNA decay (NMD) pathway where it partners with Upf1 to target and degrade mRNAs containing premature stop codons. These pathways ensure cellular integrity and protein synthesis regulation.\u003cbr\u003e\nDisruptions in Pat1b are linked to neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS) and conditions like intellectual disability. In ALS a failure in precise mRNA surveillance and decay pathways leads to toxic buildup of improperly processed mRNAs implicating Pat1b along with proteins such as TDP-43. In the context of intellectual disabilities altered mRNA metabolism involving Pat1b and its interaction with proteins like FMRP can affect neuronal function and development highlighting its significance for normal cognitive function.\u003c\/p\u003e","brand":"Abcam","offers":[{"title":"Default Title","offer_id":46845178642601,"sku":"ab259033","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/abcam-ab259033","provider":"Iright","version":"1.0","type":"link"}